Unknown

Dataset Information

0

Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe.


ABSTRACT:

Objectives

The efficacy and safety of certolizumab pegol (CZP), an Fc-free, PEGylated anti-TNF, in axial spondyloarthritis (axSpA) has been established in clinical trial settings. We report CZP effectiveness and safety in European clinical practice in patients with axSpA, including radiographic (r-) and non-radiographic (nr-) axSpA.

Methods

CIMAX (NCT02354105), a European non-interventional multicentre prospective study, observed CZP treatment response and safety over 12 months in a real-world axSpA cohort. The primary outcome was change from baseline in BASDAI to week 52, with additional outcomes pertaining to effectiveness and safety. Patients who received ≥1 dose CZP were followed up for adverse events, and those with baseline and ≥1 post-baseline BASDAI assessment were included in effectiveness analyses.

Results

A total of 672 patients (r-axSpA: 469; nr-axSpA: 201; unconfirmed diagnosis: 2) from 101 sites received ≥1 dose of CZP, of whom 564 (r-axSpA: 384; nr-axSpA: 179; unconfirmed: 1) were included in the effectiveness analyses. The mean baseline BASDAI was 6.1 in the overall axSpA population and r-axSpA and nr-axSpA subpopulations. At week 52, the mean (s.d.) change in BASDAI was -2.9 (2.3; n = 439); for r-axSpA and nr-axSpA, it was -2.9 (2.2; n = 301) and -2.8 (2.4; n = 137), respectively (P <0.0001 for all). Similar improvements were seen across other axSpA disease measures. In total, 37.9% (255/672) patients experienced adverse events, and 1.8% (12/672) experienced ≥1 serious adverse events.

Conclusion

Improvements observed in signs and symptoms of axSpA following one year of CZP treatment in real-world clinical practice were similar to those from previous randomized clinical trials, with no new safety concerns.

SUBMITTER: Baraliakos X 

PROVIDER: S-EPMC7785316 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe.

Baraliakos Xenofon X   Witte Torsten T   De Clerck Luc L   Frediani Bruno B   Collantes-Estévez Eduardo E   Katsifis Gkikas G   VanLunen Brenda B   Kleine Elisabeth E   Hoepken Bengt B   Bauer Lars L   Goodson Nicola N  

Rheumatology (Oxford, England) 20210101 1


<h4>Objectives</h4>The efficacy and safety of certolizumab pegol (CZP), an Fc-free, PEGylated anti-TNF, in axial spondyloarthritis (axSpA) has been established in clinical trial settings. We report CZP effectiveness and safety in European clinical practice in patients with axSpA, including radiographic (r-) and non-radiographic (nr-) axSpA.<h4>Methods</h4>CIMAX (NCT02354105), a European non-interventional multicentre prospective study, observed CZP treatment response and safety over 12 months in  ...[more]

Similar Datasets

| S-EPMC7307216 | biostudies-literature
| S-EPMC5089650 | biostudies-literature
| S-EPMC5054930 | biostudies-literature
| S-EPMC9562975 | biostudies-literature
| S-EPMC6619287 | biostudies-literature
| S-EPMC8556993 | biostudies-literature
| S-EPMC11668535 | biostudies-literature
| S-EPMC5850296 | biostudies-literature
| S-EPMC7410911 | biostudies-literature
| S-EPMC4365732 | biostudies-literature